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Abstract
Background: Therapeutic options to effectively inhibit growth and spread of neuroendocrine
gastrointestinal tumors are still limited. As both meta-iodobenzylguanidine (MIBG) and interferon-
γ (IFNγ) cause antineoplastic effects in neuroendocrine gastrointestinal tumor cells, we investigated
the antiproliferative effects of the combination of IFNγ a n d  n o n - r a d i o l a b e l e d  M I B G  i n
neuroendocrine gut STC-1 and pancreatic carcinoid BON tumor cells.
Methods and results: IFNγ receptors were expressed in both models. IFNγ dose- and time-
dependently inhibited the growth of both STC-1 and of BON tumor cells with IC50-values of 95 ±
15 U/ml and 135 ± 10 U/ml, respectively. Above 10 U/ml IFNγ induced apoptosis-specific caspase-
3 activity in a time-dependent manner in either cell line and caused a dose-dependent arrest in the
S-phase of the cell cycle. Furthermore, IFNγ induced cytotoxic effects in NE tumor cells.
The NE tumor-targeted drug MIBG is selectively taken up via norepinephrine transporters, thereby
specifically inhibiting growth in NE tumor cells. Intriguingly, IFNγ treatment induced an upregulation
of norepinephrine transporter expression in neuroendocrine tumors cells, as determined by semi-
quantitative RT-PCR. Co-application of sub-IC50 concentrations of IFNγ and MIBG led to additive
growth inhibitory effects, which were mainly due to increased cytotoxicity and S-phase arrest of
the cell cycle.
Conclusion:  Our data show that IFNγ exerts antiproliferative effects on neuroendocrine
gastrointestinal tumor cells by inducing cell cycle arrest, apoptosis and cytotoxicity. The
combination of IFNγ with the NE tumor-targeted agent MIBG leads to effective growth control at
reduced doses of either drug. Thus, the administration of IFNγ alone and more so, in combination
with MIBG, is a promising novel approach in the treatment of neuroendocrine gastrointestinal
tumors.
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Background
Gastrointestinal neuroendocrine (NE) tumors represent a
rare and rather heterogeneous tumor entity. Almost half
of the metastatic NE gastrointestinal tumors release exces-
sive amounts of biogenic amines and/or neuropeptides
thereby causing a characteristic hypersecretion syndrome.
The often bizarre clinical symptoms are generally well
controlled by somatostatin analogues or interferon-α
(IFNα) [1,2]. However, further growth and spread is gen-
erally not prevented on the long by either biotherapy or
conventional chemotherapy. Thus, innovative treatment
strategies should be developed that are both effective and
well tolerated.
A promising approach for novel treatment of NE gastroin-
testinal tumor disease may be the modulation of the IFNγ-
receptor system. The immunomodulatory lymphokine
IFNγ modulates biological responses by binding to its
cognate receptor thereby activating members of a tran-
scription factor family termed STAT (signal transducers
and activators of transcription) [3]. IFNγ-induced STAT
signaling and STAT-associated induction of interferon reg-
ulatory factors (IRFs) have been shown to exert key regu-
latory function for proliferation, differentiation and
survival [4]. The underlying mechanisms of IFNγ-induced
growth inhibition show a broad spectrum, including the
induction of cell cycle arrest, apoptosis and cytotoxcicity
[5,6].
Although interferons are known to evoke growth regula-
tory effects in many tissues, the effectiveness of IFN-
induced growth inhibition varies between the various cell
types. Thus, growth control observed in a given cell type
does not allow to predict similar effects of IFNγ on tissues
of other origin [7].
IFNγ-induced growth inhibition in NE gastrointestinal
tumors has not yet been evaluated in great detail. Here we
examine the antineoplastic potency of IFNγ alone or in
combination with non-radiolabeled MIBG in NE gas-
trointestinal tumor cells of the gut and pancreas.
In its radiolabeled form the norepinephrine analog MIBG
is an established diagnostic and therapeutic agent in neu-
roendocrine tumors expressing plasma membrane bound
norepinephrine transporters [8-10]. Recently, we and oth-
ers could show that even its non-radiolabeled form, the
so-called "cold MIBG" can effectively inhibit the growth
of neuroendocrine tumor cells [11,12]. Since IFNγ has
been reported to upregulate the MIBG-transporting nore-
pinephrine transporter in neuroblastoma cells [13], it was
intriguing to evaluate, whether this also held true for NE
gastrointestinal tumors cells and whether such an upregu-
lation could boost the antineoplastic potency of cold
MIBG in NE tumor cells.
Methods
Cell lines
Human pancreatic carcinoid BON cells [14,15] were
maintained in a 1:1 mixture of DMEM, and F12K medium
containing 10% FCS (Biochrom, Berlin, Germany) and
1% L-glutamine. The murine intestinal neuroendocrine
tumor cell line STC-1, which was a gift from Dr. D. Hana-
han (University of California, San Francisco, CA), was
maintained in DMEM supplemented with 15% horse
serum (Biochrom, Berlin, Germany), 2.5% FCS (Bio-
chrom) and 1% L-glutamine [16]. The neuroendocrine-
differentiated human colorectal cancer cell line Colo 320
DM [17] was maintained in standard RPMI 1640
medium, complemented with 10% FCS. All cell lines were
kept at 37°C in a humidified atmosphere (5% CO2).
Drugs
IFNγ and non-radiolabeled meta-iodobenzylguanidine
(MIBG) were purchased from Sigma (München, Ger-
many). Stock solutions were prepared in water or DMSO,
respectively, and stored at -20°C. The drugs were diluted
in fresh media before each experiment. In all experiments,
the final DMSO concentration was <0.5%. To evaluate the
effects of IFNγ and/or MIBG, cells were incubated with
either control medium or medium containing rising con-
centrations of the respective drugs. Media were changed
daily to ensure constant drug concentrations in the incu-
bation medium.
RT-PCR
Semi-quantitative analysis of mRNA expression of the
human plasma membrane bound norepinephrine trans-
porter (hNET) and the housekeeping gene β-actin was car-
ried out by RT-PCR with the number of cycles at which the
band intensity increased linearly with the amount of
mRNA used [18].
Total RNA was extracted from cultured cell lines with
RNAClean following the recommendation of the manu-
facturer (Hybaid, London, UK). Reverse transcription and
PCR reactions were carried out as described elsewhere in
detail [19]. To eliminate any possible contamination with
genomic DNA, RNAs were treated with 1 U DNAse I
(Gibco, Karlsruhe, Germany) per µg RNA for 15 min at
room temperature. Purified RNA was reverse transcribed
into cDNA using oligo-dT-primers and the SuperScript
Preamplification-Kit (Gibco). PCR reactions were carried
out in a total volume of 50 µl containing 400 nM of each
primer, 200 µM of each dNTP (Pharmacia, Uppsala, Swe-
den), 50 mM KCl, 1.5 mM MgCl2, 10 mM Tris and 1 U
Taq-Polymerase (Pharmacia). PCR was performed in a
Peltier thermocycler (PTC-200, MJ Research, Watertown,
MA) with primers and at the conditions indicated in table
1.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/23
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Measurement of growth inhibition
Changes in cell number of BON and STC-1 cells were
determined by crystal violet staining after incubation with
rising drug concentrations (IFNγ: 0–500 U/ml; MIBG: 0–
100 µM) for up to 5 days. Measurements were performed
as described [20]. Cells were washed with PBS and fixed
with 1% glutaraldehyde. After another washing step, cells
were stained with 0.1% crystal violet. The unbound dye
was removed by washing. Crystal violet that had absorbed
onto the cells was solubilized with 0.2% Triton X-100.
Then light extinction was analyzed at 570 nm using an
ELISA reader.
Cell cycle analysis
Cell cycle analysis was performed by the method of Vin-
delov and Christensen, as described previously [21]. Cells
were trypsinized, washed, and the nuclei were isolated
using CycleTest PLUS DNA Reagent Kit (Becton Dickin-
son, Heidelberg, Germany). DNA was stained with pro-
pidium iodide according to the manufacturers'
instructions. The DNA content of the nuclei was detected
by flow cytometry and analyzed using CellFit software
(Becton Dickinson, Heidelberg, Germany).
Caspase-3 activity assay
To determine apoptosis the activity of caspase-3, a key
enzyme in the apoptotic cascade was measured. Prepara-
tion of cell lysates and determination of caspase-3 activity
was performed as described previously [22]. The activity
of caspase-3 was calculated from the cleavage of the fluor-
ogenic substrate DEVD-AMC (Calbiochem-Novabio-
chem, Bad Soden, Germany). Cell lysates were incubated
with substrate solution (caspase-3 substrate AC-DEVD-
AMC 20 µg/ml, HEPES 20 mM, glycerol 10%, DTT 2 mM,
pH 7.5) for 1 h at 37°C, and the cleavage of DEVD-AMC
was measured fluorometrically with a VersaFluor fluor-
ometer (excitation: 360 nm emission: 460 nm) from Bio-
rad, Munich, Germany.
Determination of cytotoxicity
Cells were seeded at a density of 5,000 cells/well into 96-
well microtiter plates and incubated with IFNγ (0–500 U/
ml) or MIBG (0–50 µM) or the combination of both.
Release of the cytoplasmic enzyme lactate dehydrogenase
(LDH), indicating cytotoxicity, was measured after 48 h of
incubation by using the colorimetric kit from Roche as
described elsewhere [20,23]. Background release obtained
by measuring LDH release of untreated cells was sub-
tracted. Maximum release of LDH was obtained by adding
100 µl of 2% Triton X-100 to untreated cells. For determi-
nations, 100 µl of each sample were transferred to a 96-
well microtiter plate; 100 µl of LDH assay reagent were
added to each well and incubated for 30 min at room tem-
perature in the dark. The absorbance of samples was then
measured at 490 nm. No significant LDH release was
detected in the tissue culture medium alone nor in drug-
containing incubation medium.
Statistical analysis
The antineoplastic effects of the various substances and
vehicles were compared by the unpaired, two-tailed
Mann-Whitney U-test. The unpaired student t-test  was
used for cell cycle analysis. P values were considered to be
significant at <0.05. If not stated otherwise, all functional
experiments were performed in quadruplicate.
Results
Expression of IFNγ receptors in NE gastrointestinal tumor 
cells
To monitor IFNγ receptors (IFNγR) in human pancreatic
carcinoid BON cells, mRNA expression of IFNγR was eval-
uated by RT-PCR. Using specific primers directed against
the  α-chain of the human IFNγR [24], we detected a
robust expression of PCR-amplificates of the expected size
(Fig. 1). The neuroendocrine-differentiated colorectal car-
cinoma cell line Colo320 DM served as a positive control.
IFNγR expression in murine intestinal NE STC-1 tumor
cells has already been demonstrated by cDNA array anal-
ysis [11].
Table 1: Primer sequences and PCR conditions used to evaluate the expression of the transcripts indicated
Genes Primers (5'-3') Product 
size (bp)
Denaturing temperature 
and time (s)
Annealing temperature 
and time (s)
Extension temperature 
and time (s)
number 
of cycles
IFNγR F:ACgCAgAAggAAgATgATTgTgACg
R:TCTATTggAgTCAgATggCTgCCC
590 94°C (30) 63°C (90) 72°C (90) 32
hNET F:CTggTggTgAAggAgCgCAACggC
R:ATgTgATgAATCCCgCTgCTCTCg
241 94°C (60) 63°C (60) 72°C (60) 32
β-actin F:ATCATgTTTgAgACCTTCAACAC
R:TCTgCgCAAgTTAggTTTTgTC
822 94°C (60) 63°C (60) 72°C (60) 32
All templates were initially denaturated for 5 min at 95°C and the amplification was followed by a final extension temperature of 72°C for 7 min.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/23
Page 4 of 14
(page number not for citation purposes)
Growth inhibition by IFNγ
Changes in cell number induced by IFNγ were studied by
performing crystal violet assays. IFNγ (0–500 U/ml) time-
and dose-dependently inhibited the growth of both BON
and STC-1 cells. After 5 days of incubation a decrease in
cell number of up to 90% was observed in BON cells (Fig.
2a). In slower growing STC-1 cells a decrease of up to 75%
was observed after 5 days of incubation (Fig. 2b). The IC50
values of IFNγ, determined after 72 h of incubation,
amounted to 135 ± 10 U/ml in BON cells and 95 ± 15 U/
ml in STC-1 cells.
Additive antiproliferative effects of IFNγ and MIBG
Recently, we showed that non-radiolabeled MIBG specifi-
cally inhibited the growth of norepinephrine transporter
(NET)-expressing STC-1 tumor cells (IC50 ~ 8 µM) and
that MIBG-treatment increased the expression of IFNγ
receptors. Vice versa, IFNγ also enhanced MIBG-uptake
[13]. Hence, we additionally evaluated antiproliferative
effects of a combination treatment of NE gastrointestinal
tumor cells with IFNγ and MIBG.
In STC-1 cells sub-IC50 concentrations of IFNγ (10–100 U/
ml) and MIBG (1–5 µM) produced impressive additive
growth inhibitory effects (Fig. 3a). The combination of
100 U/ml IFNγ with 5 µM MIBG decreased the prolifera-
tion of STC-1 cells by 95%. Such an antiproliferative effect
was reached by MIBG alone only with concentrations of at
least 25 µM.
Using RT-PCR we also demonstrated the expression of
plasma membrane bound NET in BON cells which had
not yet been investigated with regard to NET expression
(Fig. 4a). Proliferation assays revealed that MIBG (1–100
µM) dose- and time-dependently inhibited the growth of
BON cells by up to 68 ± 3.4%. The IC50 value of MIBG,
determined after 48 h of incubation, amounted to 47.4 ±
2.1 µM being distinctly higher than in STC-1 cells. Pre-
treating BON cells with IFNγ (10–500 U/ml) influenced
the expression of MIBG-transporting NET. Semiquantita-
tive RT-PCR revealed an IFNγ-induced increase of NET
expression in BON cells by up to 200% after 48 h (Fig.
4b). However, upregulation of NET expression did not
result in an overadditive antiproliferative effect of IFNγ
(10–100 U/ml) plus MIBG (10–20 µM). Like in STC-1
cells, additive antiproliferative effects of IFNγ and MIBG
were observed in BON cells (Fig. 3b). The combination of
100 U/ml IFNγ with 10 µM MIBG produced antiprolifera-
tive effects that were comparable to those achieved by 50
µM MIBG on its own.
IFNγ and cell cycle regulation
Flow cytometric analysis revealed that challenging BON
cells for 48 h with rising concentrations of IFNγ (0–500 U/
ml) dose-dependently arrested the cells in the S-phase of
the cell cycle, thereby decreasing the proportion of cells in
the G2/M-phase. S-phase arrest was significant for 250–
500 U/ml IFNγ (Fig. 5). The effect of MIBG treatment on
the cell cycle of BON cells was also evaluated. In contrast
to slow-growing STC-1 cells, not displaying cell cycle
arresting effects in response to MIBG-treatment [13], BON
cells showed a significant and dose-dependent arrest in
the G0/G1-phase of the cell cycle after treatment with
MIBG (10–50 µM). Accordingly, the proportion of cells in
the G2/M-phase decreased.
Co-application of IFNγ (10–100 U/ml) and MIBG (50
µM) resulted in an abrogation of the MIBG-induced G0/
G1-phase arrest, while the proportion of cells in the S-
phase significantly increased as compared to MIBG-treat-
ment alone. Interestingly, the S-phase arrest induced by
combination treatment with 100 U/ml IFNγ and 50 µM
MIBG was as strong as the one achieved by 500 U/ml IFNγ
alone (Fig. 5).
Proapoptotic effects of IFNγ
To check whether an induction of programmed cell death
contributed to the antineoplastic effects of IFNγ, we inves-
tigated IFNγ-induced activation of caspase-3, a key
enzyme in the apoptotic signaling pathway. Above 10 U/
Expression of IFNγ receptors (IFNγR) in neuroendocrine  gastrointestinal tumor cells Figure 1
Expression of IFNγ receptors (IFNγR) in neuroendo-
crine gastrointestinal tumor cells. mRNA expression of 
IFNγR was evaluated in human pancreatic carcinoid BON 
tumor cells (lane 3). Neuroendocrine differentiated colorec-
tal carcinoma cells (Colo320 DM) served as positive control 
for IFNγR (lane 4). β-actin was used as loading control (lane 
1: BON, lane 2: Colo320 DM). PCR products were visualized 
by gel electrophoresis on an ethidium bromide-stained agar-
ose gel. M: 100 bp DNA ladder.
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IFNγ-induced growth inhibition Figure 2
IFNγ-induced growth inhibition Rising concentrations of IFNγ for 5 days led to a time- and dose-dependent growth inhibi-
tion of neuroendocrine gastrointestinal tumor cells, as measured by crystal violet staining. The growth of BON tumor cells was 
inhibited with an IC50 value of 135 ± 10 U/ml (A). STC-1 cells displayed an IC50 value of about 100 U/ml (95 ± 15 U/ml) (B). 
Data are given as percentage of untreated controls (means ± SEM of 4 experiments). *, statistical significance (p < 0.05) com-
pared to untreated controls.
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Antiproliferative effects of combination treatment with IFNγ and MIBG Figure 3
Antiproliferative effects of combination treatment with IFNγ and MIBG A combination treatment with sub-IC50 con-
centrations of IFNγ and MIBG for 72 h led to additive growth inhibitory effects in STC-1 (A) and BON cells (B). Black bars 
indicate the values of a calculated additive growth inhibition. Data are given as percentage of untreated controls (means ± SEM 
of 3 experiments).
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mRNA expression of human norepinephrine transporters (hNET) Figure 4
mRNA expression of human norepinephrine transporters (hNET) mRNA expression of norepinephrine transporters 
was evaluated in BON cells. A: Transcripts specific for hNET were detected by RT-PCR (lane 1). β-actin was used as loading 
control (lane 2). PCR products were visualized by gel electrophoresis on an ethidium bromide-stained agarose gel. M: 100 bp 
DNA ladder. B: Up-regulation of hNET expression by IFNγ. Semi-quantitative RT-PCR revealed a dose-dependent induction of 
hNET expression in BON cells by IFNγ after 48 h. Data are given as means ± SEM of 2 experiments.
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ml IFNγ induced caspase-3 activation in both STC-1 and
BON cells after 48 h of incubation (Fig. 6a). No significant
increase in IFNγ-induced caspase-3 activity was observed
at concentrations higher than 100 U/ml or 250 U/ml
IFNγ. Unexpectedly, co-treatment with IFNγ (10–100 U/
ml) plus MIBG (1–2 µM for STC-1 cells; 10–20 µM for
BON cells) led to subadditive caspase-3 activation in
either BON or STC-1 cells (Fig 6b,6c).
IFNγ-induced cytotoxicity
Cytotoxic loss of cellular membrane integrity was meas-
ured by LDH release assay. Incubating BON cells with 10–
500 U/ml IFNγ for 48 h resulted in a pronounced and
dose-dependent increase in LDH release (Fig. 7a). Addi-
tionally, we analyzed MIBG-induced cytotoxicity in BON
cells. Treatment with MIBG for 48 h also dose-depend-
ently increased the LDH-release of BON cells (Fig. 7b).
The combination of IFNγ (10–100 U/ml) and MIBG (10–
50 µM) resulted in a marked overadditive LDH release
from BON cells (Fig. 7c). Compared to the calculated val-
ues of an assumed additive cytotoxicity (indicated as black
bars in the columns of Fig. 7c), the actual LDH-release
induced by 100 U/ml IFNγ plus 50 µM MIBG was about
32 ± 4% higher than the calculated sum. The combination
of the lowest doses of IFNγ (10 U/ml) and MIBG (10 µM)
surmounted the calculated sum of each effect by 188 ±
Induction of cell cycle arrest by IFNγ and MIBG Figure 5
Induction of cell cycle arrest by IFNγ and MIBG After 48 h of incubation IFNγ dose-dependently induced an arrest in the 
S-phase of the cell cycle of BON cells. Accordingly, the proportion of cells in the G2/M-phase decreased. Differences in the 
proportion of cells in the respective phase of cell cycle versus control were significant from 250 to 500 U/ml IFNγ (p < 0.05). 
Incubation of BON cells with MIBG for 48 h induced a dose-dependent arrest in the G0/G1-phase, while the proportion of cells 
in the G2/M-phase decreased. Differences in the proportion of cells in the respective phase of cell cycle versus control were 
significant at 10 and 50 µM MIBG (p<0.05). Combination treatment of MIBG and IFNγ abolished MIBG-induced G0/G1-phase 
arrest. Means of 4 independent experiments are shown.
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Induction of apoptosis by IFNγ and MIBG Figure 6
Induction of apoptosis by IFNγ and MIBG A: IFNγ induced apoptosis specific caspase-3 activity in BON and STC-1 cells 
after 48 h of incubation. B: MIBG-treatment (48 h) dose-dependently increased caspase-3 activity of BON cells. Interestingly, 
combination treatment with IFNγ and MIBG resulted in sub-additive caspase-3 activation. Black bars indicate the calculated 
additive values of caspase-3 activation of either combination. C: MIBG-treatment (48 h) dose-dependently increased caspase-3 
activity of STC-1 cells. Co-incubation with IFNγ and MIBG led to sub-additive caspase-3 activation. Black bars indicate the cal-
culated additive values of caspase-3. Data are given as means ± SEM of 3 (STC-1) or 4 (BON) independent experiments. *, sta-
tistical significance (p < 0.05) compared with untreated controls.
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12%. Thus, the cytotoxic effect of a "low-dose combina-
tion" of IFNγ and MIBG was as pronounced as the one
obtained by 500 U/ml IFNγ alone.
Discussion
Although excellent control of tumor-associated hyperse-
cretion syndromes of neuroendocrine gastrointestinal
tumors can be achieved by biotherapy with somatostatin
analogs or IFNα, systemic treatment options to inhibit the
growth and further spread of metastatic neuroendocrine
tumors are still unsatisfactory. For instance, IFNα
although excellently controling hypersecretion in most
cases [2], has been shown to cause only a partial tumor
remission in less than 20% of treated patients [1,7,26].
Novel treatment modalities are therefore needed.
Here, we report on the antineoplastic effects of IFNγ, a
cytokine which has already been shown to exert growth
inhibitory effects in vitro in several non-neuroendocrine
cancer models, including breast [27], hepatocellular [28],
ovarian [29] and colorectal carcinoma [30,31] or glioblas-
toma [32]. Also in vivo, IFNγ has been demonstrated to be
beneficial as a first line therapeutic agent for ovarian
cancer [33] or as a supportive drug for enhanced
IFNγ induced cytotoxicity Figure 7
IFNγ induced cytotoxicity. Cytotoxicity of IFNγ was evaluated by lactate dehydrogenase (LDH) release from IFNγ-treated 
BON cells. A: After 48 h of incubation, IFNγ induced a dose-dependent increase in LDH release. B: MIBG-treatment (48 h) 
also induced cytotoxicity in BON cells in a dose-dependent manner. C: Interestingly, co-treatment of BON cells with IFNγ and 
MIBG resulted in an over-additive LDH release. Black bars indicate the calculated additive values of LDH release of either com-
bination. Data are given as the relative increase in LDH release compared to untreated controls (means ± SEM of 4 independ-
ent experiments). *, statistical significance (p < 0.05) compared with untreated controls.
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chemoimmunotherapeutic regimes of metastatic
melanoma [34]. Nevertheless, in other cancers (i.e., renal
cell carcinoma or SCLC) IFNγ did not show any apprecia-
ble beneficial antineoplastic action in man [35,36], argu-
ing for a distinctive tumor species-dependent effect of the
cytokine. As IFNγ-mediated growth control of a particular
tumor type does apparently not allow to predict similar
effects in other tumor species, it was all the more impor-
tant to investigate IFNγ's antineoplastic action in neu-
roendocrine gastrointestinal tumor cells. Here we provide
evidence that IFNγ potently inhibits growth of neuroen-
docrine gastrointestinal tumor cells. When IFNγ was com-
bined with MIBG, an even more pronounced
antiproliferative effect was obtained.
As the growth pattern of NE gastrointestinal tumors exhib-
its a wide spectrum ranging from very slow to fast growing
types [37], it was important to study IFNγ-induced growth
inhibition in NE tumor cell lines with different growth
characteristics and of different origin. We chose two mod-
els of NE gastrointestinal tumor disease: First, human
pancreatic carcinoid BON cells with a doubling time of 34
h, and second, NE tumor cells of the gut (STC-1 cells) with
a doubling time of 54 h [38]. In either NE tumor model
we observed growth inhibitory effects of IFNγ with IC50
values of about 100 U/ml and maximal growth inhibition
by 75–90% at ≥250 U/ml IFNγ. As these concentrations
are within the therapeutically achievable range of IFN-
plasma levels in humans [25], IFNγ appears to be a prom-
ising agent for innovative growth inhibition of NE gas-
trointestinal tumor cells.
The signaling pathways mediating IFNγ's antineoplastic
action differ between various tumor types and lead to dis-
tinct biological responses, such as G1-arrest [39], S-phase
arrest [40,41], induction of apoptosis [24,28] and cyto-
toxicity [42].
To further characterize the antiproliferative action of IFNγ
in NE gastrointestinal tumor cells, we performed cell cycle
analyses. Flow cytometry with isolated nuclei of IFNγ-
treated BON tumor cells, revealed a significant increase in
the proportion of cells in the S-phase. Cell cycle arrest by
IFNγ in the S-phase had previously been described for
other tumors such as glioblastomas [32], but other reports
described a G0/G1-arrest in response to IFNγ treatment
[6,7,43]. The accumulation of NE gastrointestinal tumor
cells in the S-phase of the cell cycle may be of great value
for novel combination treatments with established
antimetabolic chemotherapeutics such as 5-fluorouracil,
which interfere with DNA-synthesis [44]. Thus, the S-
phase arresting cytostatic drug irinotecan enhances the
antiproliferative efficacy of 5-fluorouracil in colon cancer
[45].
Moreover, we observed an induction of apoptosis in neu-
roendocrine gastrointestinal tumor cells by IFNγ. Con-
cerning the underlying mechanisms of IFNγ-induced
apoptosis both indirect mechanisms like an increase in
TNF-α sensitivity [46], an upregulation of CD95 receptor
expression [47] or a modulation of human leukocyte anti-
gen molecules (HLA) [48], and direct mechanisms like the
upregulation and activation of caspases have been shown
[24,49]. In BON and STC-1 cells we found a dose-depend-
ent induction of apoptosis via proapoptotic caspase-3
activation. This direct mechanism has been previously
described by Detjen et al. [50] in neuroendocrine QGP-1
tumor cells. In OGP-1 cells IFNγ-mediated apoptosis was
found to require intermediate signaling steps such as
induction of the interferon regulatory factor IRF-1 and
subsequent activation of the initiator caspase-1, which
accounted for the relatively long time to response of IFNγ-
induced apoptosis. Caspase-1-mediated activation of
downstream caspases in response to IFNγ has been
reported for other cell models, like leukemia cells [51],
vascular smooth muscle cells [52] and HeLa cells [53]. It
is intriguing to speculate, that also in the BON and STC-1
tumor models IFNγ-mediated apoptosis involved such
intermediary signaling steps, since caspase-3 activation in
BON and STC-1 cells was not detectable earlier than after
48 h of incubation with IFNγ. In order to fully understand
the signaling events of IFNγ-induced apoptosis in neu-
roendocrine tumor cells further investigations are
required.
Growth inhibition of NE tumor cells by IFNγ also involves
cytotoxcicity. At least at high concentrations of IFNγ, BON
cells displayed a significant increase in LDH release.
Interestingly, at the half-maximal growth inhibitory IFNγ
concentration of 100 U/ml neither a significant increase
in cytotoxicity nor a significant S-phase arrest could be
observed, and only caspase-3 activity was significantly
increased. Thus, at lower concentrations IFNγ appears to
control growth of NE tumor cells mainly by apoptosis,
whereas at higher concentrations other mechanisms are
involved.
The second goal of our study was to explore the growth
inhibitory effects of a combination treatment of IFNγ and
non-radiolabeled meta-iodobenzylguanidine (MIBG).
The rationale for investigating this particular combinba-
tion was first, that non-radiolabeled MIBG was a potent
NE tumor-specific antineoplastic drug [11,38], and sec-
ond, that IFNγ enhanced the uptake of MIBG by increas-
ing the expression of norepinephrine transporters in
neuroblastoma cells [13]. Moreover, we recently showed
that MIBG induced an overexpression of IFNγ-receptors in
NE gastrointestinal tumor cells [11]. These results sug-
gested possible synergistic action of a combination treat-
ment of IFNγ and MIBG. Intriguingly, combining sub-IC50BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/23
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concentrations of IFNγ and MIBG led to growth
inhibition of up to 95%. In STC-1 cells, the combination
of IFNγ and MIBG exeeded the maximal antiproliferative
effect of IFNγ alone by more than 20%. To achieve 90%
growth inhibition of STC-1 cells by MIBG alone, concen-
trations beyond 25 µM were needed. Thus, combining
IFNγ and MIBG allows to reduce the concentration of
either agent to one fifth without losing excellent growth
control. The same holds true for BON cells, which also
displayed enhanced growth inhibition in response to sub-
IC50 concentrations of IFNγ and MIBG. The potential of
this novel combination treatment strategy will have to be
evaluated in future clinical studies.
To further investigate underlying mechanisms of the pro-
posed combination therapy, we evaluated IFNγ-induced
norepinephrine transporter expression, apoptosis, cell
cycle regulation and cytotoxicity in BON cells. Our results
indicate that an overexpression of norepinephrine trans-
porters does not account for enhanced growth inhibition
by IFNγ plus MIBG. Although IFNγ induced the expres-
sion of norepinephrine transporters (NET) in
neuroendocrine gastrointestinal tumor cells, the IFNγ
concentrations required to achieve a marked increase in
NET expression were far above the antiproliferative IC50-
value of about 100 U/ml. Hence, our data indicate that an
enhanced MIBG-uptake due to an IFNγ-induced overex-
pression of NET cannot be achieved with IFNγ concentra-
tions, suitable for combination treatment.
Unexpectedly, the combination of MIBG and IFNγ
resulted in a sub-additive caspase-3 activation as com-
pared to treatment with either drug alone. Furthermore,
we found an abrogation of MIBG-induced G0/G1-phase
arrest in BON cells that had been co-treated with S-phase
arresting IFNγ. Thus, MIBG and IFNγ appear to modulate
distinct signaling pathways to induce apoptosis and cell
cycle arrest in NE tumor cells. Due to yet unknown inter-
ferences in the signaling events, the effects on apoptosis
and cell cycle were less pronounced and even sub-addi-
tive. Thus, it will be of future interest to identify the sign-
aling molecules involved in this interference to gain
insight into the underlying regulatory processes at the
molecular level. However, sub-additive cell cycle arrest
has already been found for other drug combinations, like
the combination of 5-fluorouracil and cisplatin in colon
cancer. In contrast to our findings the sub-additive cell
cycle arrest of 5-fluorouracil and cisplatin led to a reduced
growth inhibition than with 5-fluorouracil alone [54].
Despite of the reduced apoptosis and cell cycle arrest the
growth inhibition obtained by IFNγ plus MIBG was addi-
tive in NE tumor cells. The most likely explanation of
these conflicting results is a synergistic increase in cytotox-
icity in resopnse to IFNγ plus MIBG. While almost no
cytotoxicity was seen for either drug alone, the combina-
tion of low doses of MIBG and IFNγ led to a pronounced
and significant synergistic increase in cytotoxicity. Con-
centrations as high as 500 U/ml were needed to achieve
comparable cytotoxic effects by IFNγ alone. The underly-
ing mechanisms are yet unknown, but have to be studied
in the future. Anyway, the very fact, that co-treatment of
NE tumor cells with IFNγ and MIBG exerts such a pro-
nounced cytotoxic effect may be of potential clinical
value: As the expression of MIBG-transporting norepine-
phrine transporters in extraneuronal locations is limited
or low (e.g., heart, renal medulla, lung endothelial cells),
the relative specific and exclusive NET (over)expression in
neuroendocrine gastrointestinal tumor cells forms a basis
for NE tumor-targeted treatment [55]. Thus, a low concen-
tration of MIBG renders an ineffective concentration of
IFNγ cytotoxic in NE tumor cells. It can therefore be spec-
ulated that the combination of IFNγ with MIBG may
induce a NE tumor cell-specific killing with reduced side-
effects in normal cells. Future clinical studies will have to
clarify the actual effects in vivo.
Conclusions
Our study provides evidence that IFNγ induces both cell
cycle arrest and apoptosis in NE gastrointestinal tumor
cells. Moreover, IFNγ can be effectively combined with
non-radiolabeled MIBG in order to achieve excellent
growth control at low concentrations of either drug. Thus,
IFNγ represents a promising novel drug to be tested in
patients with metastatic NE gastrointestinal tumor
disease.
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